- Home
- PSHG vs QTTB Comparison
PSHG vs QTTB Comparison
Compare PSHG & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- QTTB
- Stock Information
- Founded
- PSHG 2010
- QTTB 2015
- Country
- PSHG Greece
- QTTB United States
- Employees
- PSHG N/A
- QTTB N/A
- Industry
- PSHG Marine Transportation
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- QTTB Health Care
- Exchange
- PSHG Nasdaq
- QTTB Nasdaq
- Market Cap
- PSHG 22.8M
- QTTB 23.3M
- IPO Year
- PSHG N/A
- QTTB N/A
- Fundamental
- Price
- PSHG $1.90
- QTTB $1.67
- Analyst Decision
- PSHG
- QTTB Hold
- Analyst Count
- PSHG 0
- QTTB 8
- Target Price
- PSHG N/A
- QTTB $24.00
- AVG Volume (30 Days)
- PSHG 108.1K
- QTTB 104.5K
- Earning Date
- PSHG 11-06-2025
- QTTB 08-06-2025
- Dividend Yield
- PSHG N/A
- QTTB N/A
- EPS Growth
- PSHG 5.84
- QTTB N/A
- EPS
- PSHG 1.56
- QTTB N/A
- Revenue
- PSHG $84,042,000.00
- QTTB N/A
- Revenue This Year
- PSHG N/A
- QTTB N/A
- Revenue Next Year
- PSHG $17.95
- QTTB N/A
- P/E Ratio
- PSHG $1.21
- QTTB N/A
- Revenue Growth
- PSHG N/A
- QTTB N/A
- 52 Week Low
- PSHG $1.31
- QTTB $1.35
- 52 Week High
- PSHG $2.34
- QTTB $53.79
- Technical
- Relative Strength Index (RSI)
- PSHG 53.02
- QTTB 42.51
- Support Level
- PSHG $1.76
- QTTB $1.62
- Resistance Level
- PSHG $1.95
- QTTB $1.82
- Average True Range (ATR)
- PSHG 0.11
- QTTB 0.16
- MACD
- PSHG -0.01
- QTTB -0.02
- Stochastic Oscillator
- PSHG 38.89
- QTTB 10.42
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.